Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of Myriberine A in preparation of medicine for treating lung cancer

A drug and lung cancer technology, applied in the application field of Myriberine A in the preparation of drugs for the treatment of lung cancer, can solve the problem of damage to normal tissues and cells, and achieve the effect of strong cytotoxicity and prominent substantive characteristics

Inactive Publication Date: 2013-09-25
严建山
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Malignant tumors are diseases that seriously threaten human life and health. Chemotherapy drugs commonly used in clinical practice can greatly damage normal tissues and cells while killing tumor cells, which limits its application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Myriberine A in preparation of medicine for treating lung cancer
  • Application of Myriberine A in preparation of medicine for treating lung cancer
  • Application of Myriberine A in preparation of medicine for treating lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1: the preparation of compound Myriberine A tablet involved in the present invention:

[0014] Take 5 grams of compound Myriberine A, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional compression.

Embodiment 2

[0015] Embodiment 2: the preparation of the compound Myriberine A capsule involved in the present invention:

[0016] Get 5 grams of compound Myriberine A, add 195 grams of starch, mix well, and make 1000 capsules.

[0017] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0018] Experimental Example 1: The Inhibitory Effect of Myriberine A on the Proliferation of Lung Cancer Cells Cultured in Vitro and the Effect on Human Normal Cells

[0019] Lung cancer cells in logarithmic growth phase (non-small cell lung cancer cell A549, large cell lung cancer cell NCI-H460, lung squamous cell carcinoma cell HTB-8 and human lung squamous cell carcinoma cell QG-5) and human normal liver cell L02 were inoculated in On a 96-well culture plate, the inoculum volume per well was 3000-4000 cells / 100uL and 6000 cells / 100uL respectively; aseptically collected 15 mL of venous blood from healthy blood donors, anticoagulated with heparin, and separated mononuclear cells by Ficoll density gradient centrifugation. A single cell suspension was prepared with RPMI1640 containing 10% fetal bovine serum, adjusted to a cell concentration of 2×105 cells / mL, and inoculated in a 96-well culture plate, 100 uL per well. After 24 hours of cell culture on each of the above-mentione...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Myriberine A in the preparation of a medicine for treating lung cancer. The compound shows a good anti-lung cancer activity, can be used in the preparation of an anti-lung cancer medicine, and belongs to the technical field of new application of medicines. Myriberine A can remarkably inhibit in vitro cultured non-small cell lung cancer cell A549, maxicell lung cancer cell NCI-H460, lung squamous carcinoma cell HTB-8 and human lung squamous cell carcinoma cell QG-5, has little effect of inhibiting human normal hepatocyte LO2 and peripheral blood lymphocyte, and shows obvious selectivity. The application of Myriberine A in the preparation of a medicine for treating lung cancer is disclosed for the first time. The matrix type belongs to a brand new matrix type, and Myriberine A has an unexpectedly strong activity of inhibiting the lung carcinoma cell.

Description

technical field [0001] The present invention relates to a new application of compound Myriberine A, in particular to the application of Myriberine A in the preparation of drugs for treating lung cancer. Background technique [0002] Malignant tumors are diseases that seriously threaten human life and health. Chemotherapy drugs commonly used in clinical practice can greatly damage normal tissues and cells while killing tumor cells, which limits its application. It has become the direction and urgent task of current anticancer drug research to find highly efficient and low toxic drugs for treating tumors. Finding high-efficiency, low-toxic anticancer drugs has been considered an effective way. [0003] The compound Myriberine A involved in the present invention is published in 2012 (Sheng-Dian Huang, et al., Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton from Myrioneuron faberi.Organic Letters, 2012, 3(15), 590-593 .), the compound has a new ty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P35/00
Inventor 严建山
Owner 严建山